{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:20:17Z","timestamp":1768900817604,"version":"3.49.0"},"reference-count":76,"publisher":"Portland Press Ltd.","issue":"7","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["203814\/Z\/16\/A, A.P.D., T.L.W"],"award-info":[{"award-number":["203814\/Z\/16\/A, A.P.D., T.L.W"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["206194 and 220540\/Z\/20\/A"],"award-info":[{"award-number":["206194 and 220540\/Z\/20\/A"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>High blood pressure in the portal vein, portal hypertension (PH), is the final common pathway in liver cirrhosis regardless of aetiology. Complications from PH are the major cause of morbidity and mortality in these patients. Current drug therapy to reduce portal pressure is mainly limited to \u03b2-adrenergic receptor blockade but approximately 40% of patients do not respond. Our aim was to use microarray to measure the expression of \u223c20,800 genes in portal vein from patients with PH undergoing transplantation for liver cirrhosis (PH, n=12) versus healthy vessels (control, n=9) to identify potential drug targets to improve therapy. Expression of 9,964 genes above background was detected in portal vein samples. Comparing PH veins versus control (adjusted P-value &amp;lt; 0.05, fold change &amp;gt; 1.5) identified 548 up-regulated genes and 1,996 down-regulated genes. The 2,544 differentially expressed genes were subjected to pathway analysis. We identified 49 significantly enriched pathways. The endothelin pathway was ranked the tenth most significant, the only vasoconstrictive pathway to be identified. ET-1 gene (EDN1) was significantly up-regulated, consistent with elevated levels of ET-1 peptide previously measured in PH and cirrhosis. ETA receptor gene (EDNRA) was significantly down-regulated, consistent with an adaptive response to increased peptide levels in the portal vein but there was no change in the ETB gene (EDNRB). The results provide further support for evaluating the efficacy of ETA receptor antagonists as a potential therapy in addition to \u03b2-blockers in patients with PH and cirrhosis.<\/jats:p>","DOI":"10.1042\/bsr20240528","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T14:23:21Z","timestamp":1718115801000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein"],"prefix":"10.1042","volume":"44","author":[{"given":"Nicola\u00a0E.","family":"Owen","sequence":"first","affiliation":[{"name":"1Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, CB2 0QQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas\u00a0L.","family":"Williams","sequence":"additional","affiliation":[{"name":"1Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, CB2 0QQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet\u00a0J.","family":"Maguire","sequence":"additional","affiliation":[{"name":"1Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, CB2 0QQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhoda\u00a0E.","family":"Kuc","sequence":"additional","affiliation":[{"name":"1Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, CB2 0QQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma\u00a0E.","family":"Davenport","sequence":"additional","affiliation":[{"name":"2Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, CB10 1SA, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-3117","authenticated-orcid":false,"given":"Anthony\u00a0P.","family":"Davenport","sequence":"additional","affiliation":[{"name":"1Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, CB2 0QQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2024110714154062200_B1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.crad.2015.06.077","article-title":"Portal hypertension: a review of portosystemic collateral pathways and endovascular interventions","volume":"70","author":"Pillai","year":"2015","journal-title":"Clin. Radiol."},{"key":"2024110714154062200_B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imj.12590","article-title":"Portal hypertension: pathophysiology, diagnosis and management","volume":"45","author":"Bloom","year":"2015","journal-title":"Intern. Med. J."},{"key":"2024110714154062200_B3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"GBD 2017 Cirrhosis Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2024110714154062200_B4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol Hepatol."},{"key":"2024110714154062200_B5","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J. Hepatol."},{"key":"2024110714154062200_B6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMra0901512","article-title":"Management of varices and variceal hemorrhage in cirrhosis","volume":"362","author":"Garcia-Tsao","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2024110714154062200_B7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-017-0966-6","article-title":"Advances and challenges in cirrhosis and portal hypertension","volume":"15","author":"Berzigotti","year":"2017","journal-title":"BMC Med."},{"key":"2024110714154062200_B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11901-023-00598-4","article-title":"Emerging therapeutic targets for portal hypertension","volume":"22","author":"Felli","year":"2023","journal-title":"Curr. Hepatol. Rep."},{"key":"2024110714154062200_B9","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/jcm12175586","article-title":"New developments and challenges in liver transplantation","volume":"12","author":"Khalil","year":"2023","journal-title":"J. Clin. Med."},{"key":"2024110714154062200_B10","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13943.1","article-title":"Managing portal hypertension in patients with liver cirrhosis","volume":"7","author":"Sauerbruch","year":"2018","journal-title":"F1000Res"},{"key":"2024110714154062200_B11","first-page":"617","article-title":"The use of nonselective beta blockers for treatment of portal hypertension","volume":"13","author":"Garcia-Tsao","year":"2017","journal-title":"Gastroenterol. Hepatol. (N.Y.)"},{"key":"2024110714154062200_B12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.5694\/mja18.00754","article-title":"Patient-centred care for cirrhosis: a key role for chronic disease management","volume":"209","author":"Papaluca","year":"2018","journal-title":"Med. J. Aust."},{"key":"2024110714154062200_B13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1053\/jhep.2002.33469","article-title":"Somatostatin and analogues in portal hypertension","volume":"35","author":"Abraldes","year":"2002","journal-title":"Hepatology"},{"key":"2024110714154062200_B14","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/hep.27006","article-title":"Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage","volume":"60","author":"Seo","year":"2014","journal-title":"Hepatology"},{"key":"2024110714154062200_B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to \u03b2-blockers in compensated cirrhosis with portal hypertension","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology"},{"key":"2024110714154062200_B16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/hep.23617","article-title":"Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding","volume":"52","author":"Lo","year":"2010","journal-title":"Hepatology"},{"key":"2024110714154062200_B17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"2024110714154062200_B18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J. Hepatol."},{"key":"2024110714154062200_B19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3350\/cmh.2020.0234","article-title":"\u03b2-Blockers in advanced cirrhosis: more friend than enemy","volume":"27","author":"Yoon","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"2024110714154062200_B20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3350\/cmh.2015.21.4.319","article-title":"Nitric oxide in liver fibrosis: the role of inducible nitric oxide synthase","volume":"21","author":"Iwakiri","year":"2015","journal-title":"Clin. Mol. Hepatol."},{"key":"2024110714154062200_B21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"2024110714154062200_B22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.phrs.2011.01.014","article-title":"Role of endothelin in the cardiovascular system","volume":"63","author":"Rodr\u00edguez-Pascual","year":"2011","journal-title":"Pharmacol. Res."},{"key":"2024110714154062200_B23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lfs.2013.12.024","article-title":"The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases?","volume":"118","author":"Rodr\u00edguez-Pascual","year":"2014","journal-title":"Life Sci."},{"key":"2024110714154062200_B24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/19768354.2019.1595141","article-title":"Endothelin-converting enzyme-1 expression in acute and chronic liver injury in fibrogenesis","volume":"23","author":"Cho","year":"2019","journal-title":"Anim. Cells Syst. (Seoul)"},{"key":"2024110714154062200_B25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"2024110714154062200_B26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s44161-023-00347-2","article-title":"Current and future strategies for targeting the endothelin pathway in cardiovascular disease","volume":"2","author":"Abraham","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"2024110714154062200_B27","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJM199212173272502","article-title":"Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome","volume":"327","author":"Moore","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"2024110714154062200_B28","first-page":"735","article-title":"Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function","volume":"21","author":"Gerbes","year":"1995","journal-title":"Hepatology"},{"key":"2024110714154062200_B29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3109\/00365519609088803","article-title":"Endothelins in chronic liver disease","volume":"56","author":"M\u00f8ller","year":"1996","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"2024110714154062200_B30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.510270222","article-title":"Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells","volume":"27","author":"Rockey","year":"1998","journal-title":"Hepatology"},{"key":"2024110714154062200_B31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1386-6346(01)00077-8","article-title":"Clinical investigation of endothelin-1 and nitric oxide in patients with portal hypertension focusing on plasma levels and immunohistological staining of liver tissues","volume":"21","author":"Ohara","year":"2001","journal-title":"Hepatol. Res."},{"key":"2024110714154062200_B32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cyto.2015.05.025","article-title":"Endothelin 1 and transforming growth factor-\u03b21 correlate with liver function and portal pressure in cirrhotic patients","volume":"76","author":"Wereszczynka-Siemiatkowska","year":"2015","journal-title":"Cytokine"},{"key":"2024110714154062200_B33","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/0016-5085(93)90654-U","article-title":"The endothelin-1 binding site in rat liver tissue: Light- and electron-microscopic autoradiographic studies","volume":"104","author":"Gondo","year":"1993","journal-title":"Gastroenterology"},{"key":"2024110714154062200_B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0024-3205(95)02255-4","article-title":"Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats","volume":"58","author":"Gandhi","year":"1996","journal-title":"Life Sci."},{"key":"2024110714154062200_B35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/hep.510270315","article-title":"Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction","volume":"27","author":"Kaneda","year":"1998","journal-title":"Hepatology"},{"key":"2024110714154062200_B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1034\/j.1600-0676.2000.020001003.x","article-title":"Morphological mechanisms for regulating blood flow through hepatic sinusoids","volume":"20","author":"McCuskey","year":"2000","journal-title":"Liver"},{"key":"2024110714154062200_B37","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1172\/JCI118925","article-title":"Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing","volume":"98","author":"Rockey","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2024110714154062200_B38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00535-007-2093-1","article-title":"An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation","volume":"42","author":"Watanabe","year":"2007","journal-title":"J. Gastroenterol."},{"key":"2024110714154062200_B39","doi-asserted-by":"publisher","first-page":"G27","DOI":"10.1152\/ajpgi.90405.2008","article-title":"Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease","volume":"297","author":"Feng","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2024110714154062200_B40","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1139\/Y10-038","article-title":"Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats","volume":"88","author":"Cavasin","year":"2010","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"2024110714154062200_B41","first-page":"37","article-title":"Effect of endothelin A receptor antagonist on hepatic hemodynamics in cirrhotic rats. Implications for endothelin-1 in portal hypertension","volume":"36","author":"Takashimizu","year":"2011","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"2024110714154062200_B42","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"2024110714154062200_B43","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2024110714154062200_B44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. Royal Stat. Soc. Series B (Methodological)"},{"key":"2024110714154062200_B45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13073-016-0384-y","article-title":"XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits","volume":"8","author":"Fang","year":"2016","journal-title":"Genome Med."},{"key":"2024110714154062200_B46","doi-asserted-by":"publisher","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2024","volume":"52","author":"Harding","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"2024110714154062200_B47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.lfs.2012.05.008","article-title":"Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues","volume":"91","author":"Maguire","year":"2012","journal-title":"Life Sci."},{"key":"2024110714154062200_B48","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1002\/hep4.2091","article-title":"Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model","volume":"6","author":"Rabiee","year":"2022","journal-title":"Hepatol Commun."},{"key":"2024110714154062200_B49","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/01.RES.0000195611.59811.ab","article-title":"Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress","volume":"97","author":"Dixit","year":"2005","journal-title":"Circ. Res."},{"key":"2024110714154062200_B50","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI200418004","article-title":"HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3","volume":"113","author":"Nofer","year":"2004","journal-title":"J. Clin. Invest."},{"key":"2024110714154062200_B51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1161\/HYPERTENSIONAHA.117.09088","article-title":"S1PR1 (Sphingosine-1-Phosphate Receptor 1) signaling regulates blood flow and pressure","volume":"70","author":"Cantalupo","year":"2017","journal-title":"Hypertension"},{"key":"2024110714154062200_B52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1124\/jpet.119.257931","article-title":"Short periods of hypoxia upregulate sphingosine kinase 1 and increase vasodilation of arteries to sphingosine 1-phosphate (S1P) via S1P3","volume":"371","author":"Alganga","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024110714154062200_B53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"2024110714154062200_B54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s41030-023-00251-x","article-title":"Safety of macitentan for the treatment of portopulmonary hypertension: real-world evidence from the combined OPUS\/OrPHeUS studies","volume":"10","author":"Kim","year":"2024","journal-title":"Pulm. Ther."},{"key":"2024110714154062200_B55","first-page":"1675","article-title":"Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension","volume":"10","author":"Monaco","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"2024110714154062200_B56","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.lfs.2012.02.003","article-title":"Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice","volume":"91","author":"Ling","year":"2012","journal-title":"Life Sci."},{"key":"2024110714154062200_B57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"2024110714154062200_B58","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/liv.14757","article-title":"Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: a proof of concept study","volume":"41","author":"Zipprich","year":"2021","journal-title":"Liver Int."},{"key":"2024110714154062200_B59","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00228-011-1157-6","article-title":"Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis","volume":"68","author":"Lebrec","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024110714154062200_B60","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/gut.2005.077453","article-title":"Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial","volume":"55","author":"Tripathi","year":"2006","journal-title":"Gut"},{"key":"2024110714154062200_B61","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"2024110714154062200_B62","article-title":"A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis"},{"key":"2024110714154062200_B63","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-022-01708-0","article-title":"Clazosentan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"2024110714154062200_B64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"2024110714154062200_B65","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/jcm10040702","article-title":"Update on new aspects of the renin-angiotensin system in hepatic fibrosis and portal hypertension: implications for novel therapeutic options","volume":"10","author":"Rajapaksha","year":"2021","journal-title":"J Clin Med."},{"key":"2024110714154062200_B66","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases","volume":"67","author":"Denton","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"2024110714154062200_B67","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int."},{"key":"2024110714154062200_B68","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/ndt\/gfad078","article-title":"The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan","volume":"38","author":"Veenit","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"2024110714154062200_B69","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2024110714154062200_B70","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"2024110714154062200_B71","article-title":"A two part phase IIa\/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension","author":"ZEAL Study","year":"2022"},{"key":"2024110714154062200_B72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/gastro\/gow018","article-title":"Oesophageal and gastric varices: historical aspects, classification and grading: everything in one place","volume":"4","author":"Philips","year":"2016","journal-title":"Gastroenterol. Rep. (Oxf.)"},{"key":"2024110714154062200_B73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MED.0000000000000528","article-title":"Peptide-based therapy in portal hypertension","volume":"27","author":"Mohanty","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diab. Obes."},{"key":"2024110714154062200_B74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0676.1996.tb00733.x","article-title":"Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study","volume":"16","author":"Zironi","year":"1996","journal-title":"Liver"},{"key":"2024110714154062200_B75","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/gast.2001.21619","article-title":"Octreotide and its effects on portal circulation","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"2024110714154062200_B76","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/liv.12360","article-title":"Beta-blockers in portal hypertension: new developments and controversies","volume":"34","author":"Tripathi","year":"2014","journal-title":"Liver Int."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20240528\/963192\/bsr-2024-0528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20240528\/963192\/bsr-2024-0528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T14:15:56Z","timestamp":1730988956000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/44\/7\/BSR20240528\/234551\/Microarray-analysis-demonstrates-up-regulation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20240528","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7]]},"article-number":"BSR20240528"}}